

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2021-00881
Patent 9,254,338 B2

**PETITIONER'S OBJECTIONS TO
ADMISSIBILITY OF EVIDENCE SUBMITTED BY PATENT OWNER**

Pursuant to 37 C.F.R. § 42.64(b), Petitioner Mylan Pharmaceuticals Inc. (“Petitioner”), hereby objects as follows to the admissibility of evidence filed by Patent Owner Regeneron Pharmaceuticals, Inc. (“Regeneron” or “Patent Owner”), in conjunction with the Patent Owner Preliminary Response, filed on August 16, 2021, and Patent Owner Consolidated Sur-Reply, filed on October 6, 2021.

In this paper, a reference to “FRE” means the Federal Rules of Evidence, a reference to “CFR” means the Code of Federal Regulations, and “’338 patent” means U.S. Patent No. 9,254,338. All objections under FRE 802 (hearsay) apply to the extent Patent Owner relies on the exhibits identified in connection with that objection for the truth of the matter asserted therein.

Exhibit descriptions provided in this table are Patent Owner’s exhibit list and are used for identification purposes only. The use of the description does not indicate that Petitioner agrees with the descriptions or characterizations of the documents.

Ex. No.	Description	Objections
2001	Expert Declaration of Dr. Diana V. Do, M.D.	A, C, D, E, F, G, H, M, N, O, Q, S, T
2002	Curriculum Vitae of Dr. Diana Do	A, B, C, D, E, F, G, H, I, M, N, O, T
2003	Lucentis (ranibzumab injection) label, revised June 2010	A, C, D, E, F, G, H, M, N, O
2004	Ex. (a)(1)(a) to Tender Offer Statement to Momenta, filed with SEC on September 2, 2020	A, B, C, D, E, F, G, H, I, M, N, O, T
2005	Press Release, Johnson & Johnson, <i>Johnson &</i>	A, B, C, D, E, F, G,

Ex. No.	Description	Objections
	<i>Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases</i> , dated August 19, 2020	H, M, N, O, T
2006	Press Release, Johnson & Johnson, <i>Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.</i> , dated October 1, 2020	A, B, C, D, E, F, G, H, M, N, O, T
2007	Press Release, THOMAS REUTERS INTEGRITY "VEGF Trap-Eye final phase II results in age-related macular degeneration presented at 2008 Retina Society Meeting" (September 2008)	A, B, C, D, E, F, G, H, M, N, O, T
2010	Excerpts from J.M. Berg <i>et al.</i> , <i>Biochemistry</i> (5 th Ed. 2002)	A, C, D, E, F, G, H, I, M, N, O
2012	P. Iacono <i>et al.</i> , <i>Antivascular Endothelial Growth Factor in Diabetic Retinopathy</i> , <i>Dev. Ophthalmol.</i> 46:39-53 (2010)	A, C, D, E, F, G, H, M, N, O
2014	J.W. Moroney <i>et al.</i> , <i>Aflibercept in Epithelial Ovarian Carcinoma</i> , <i>Future Oncol</i> 5(5):591-600 (2009)	A, C, D, E, F, G, H, M, N, O
2015	U.S. Patent Publication 2010/0160233 A1 to Bissery <i>et al.</i> , published June 24, 2010	A, C, D, E, F, G, H, K, M, N, O
2016	T. Hachiya <i>et al.</i> , <i>Increase in respiratory cost at high growth temperature is attributed to high protein turnover cost in Petunia x hybrida petals</i> , <i>Plant, Cell, and Environment</i> , 30:1269-1283 (2007)	A, C, D, E, F, G, H, M, N, O
2017	M. Piques <i>et al.</i> , <i>Ribosome and transcript copy numbers, polysome occupancy and enzyme dynamics in Arabidopsis</i> , <i>Molecular Systems Biology</i> 5: Article number 314 (2009)	A, C, D, E, F, G, H, M, N, O

Ex. No.	Description	Objections
2018	Jaffe et al., <i>Differential Response to Anti-VEGF Regimens in Age- Related Macular Degeneration Patients with Early Persistent Retinal Fluid</i> , Ophthalmology 2016;123:1856-1864 (2016)	A, C, D, E, F, G, H, M, N, O
2019	Eylea (afibercept) Injection label, revised May 2016	A, C, D, E, F, G, H, M, N, O
2020	A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI), NCT02247531, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT02247531?term=lampalizumab&phase=2&draw=2&rank=2	A, B, C, D, E, F, G, H, M, N, O, T
2021	A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA), NCT02247479, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT02247479?term=lampalizumab&phase=2&draw=2&rank=3	A, B, C, D, E, F, G, H, M, N, O, T
2022	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD(PANDA-2), NCT03630952, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT03630952?term=NCT03630952&draw=2&rank=1	A, B, C, D, E, F, G, H, M, N, O, T
2023	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular	A, B, C, D, E, F, G, H, M, N, O, T

Ex. No.	Description	Objections
	AMD(PANDA-1), NCT03577899, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT03577899?term=NCT03577899&draw=2&rank=1	
2024	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreal Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy, NCT01944839, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT01944839?term=fovista&phase=2&draw=2&rank=1	A, B, C, D, E, F, G, H, M, N, O, T
2025	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreal Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy, ClinicalTrials.gov (August 2, 2021), https://clinicaltrials.gov/ct2/show/NCT01940900?term=fovista&phase=2&draw=2&rank=2	A, B, C, D, E, F, G, H, M, N, O, T
2026	S. Elvidge, <i>Ophtotech's Fovista crashes out in wet AMD</i> , BIOPHARMADIVE (Aug. 14, 2017), available at, https://www.biopharmadive.com/news/ophtotech-fovista-phase-3-failure-setback-novartis/449248/	A, B, C, D, E, F, G, H, M, N, O
2027	X. Li et al., <i>Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration: Results from a 12-Month Randomized Phase 2 Study: AURORA Study</i> , Ophthalmology 2014;121:1740-1747 (2014)	A, C, D, E, F, G, H, M, N, O
2029	Bhisitkul, Robert B. and Stewart, Jay M., <i>Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration</i> ,	A, C, D, E, F, G, H, M, N, O

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.